Free Trial
NYSEAMERICAN:CCEL

Cryo-Cell International Q1 2026 Earnings Report

Cryo-Cell International logo
$3.48 +0.11 (+3.26%)
As of 01:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryo-Cell International EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cryo-Cell International Revenue Results

Actual Revenue
$7.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cryo-Cell International Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cryo-Cell International Earnings Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
Wall Street Analysts Are Neutral on Top Healthcare Picks
See More Cryo-Cell International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cryo-Cell International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cryo-Cell International and other key companies, straight to your email.

About Cryo-Cell International

Cryo-Cell International (NYSEAMERICAN:CCEL), Inc. is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth. Trained medical personnel coordinate with healthcare providers to collect cord blood and cord tissue immediately after delivery. Samples are shipped in temperature-controlled containers to Cryo-Cell’s processing laboratories, where stem cell fractions are isolated, tested for purity and viability, and ultimately cryogenically stored in liquid nitrogen tanks.

Cryo-Cell serves families across the United States and in select international markets through a network of distribution partners. In addition to its core storage offerings, the company provides customized preservation plans, educational materials and dedicated client support to prospective parents. Cryo-Cell also collaborates with research institutions and participates in industry initiatives aimed at expanding the therapeutic applications of cord blood and tissue derivatives.

Guided by an experienced management team with expertise in biotechnology, clinical operations and regulatory affairs, Cryo-Cell International continues to invest in advanced processing technologies and service expansion. The company’s focus on safety, compliance and customer engagement positions it as a leading player in the evolving field of regenerative medicine and stem cell banking.

View Cryo-Cell International Profile